Aaron Smith wrote the article about Geron and Advanced Cell Technology. It also mentioned Novocell.
In the case of the first two companies, Smith said tests could begin as early as next year. However, schedules have slipped in the past.
"'What we're seeing now in the stem cell field is like a chess match,' said Stephen Brozak, analyst for WBB Securities. 'The early moves will ultimately dictate who succeeds in the stem cell space.'"Geron's product involves spinal cord injuries and ACT's vision loss. Novocell is looking at diabetes.